Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Dyslipidemias / drug therapy"'
Publikováno v:
Acta Médica Portuguesa, Vol 33, Iss 3, Pp 204-207 (2020)
In about 28% of patients, dyslipidemia has a secondary cause. Many times, the treatment of these causes can lead to the total correction of dyslipidemia. We describe the case of a 50-year-old female patient with class II obesity and primary biliary c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::fda11b37efc08098c35b9ca036f0d3f7
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944
Autor:
Maciej Banach, Stanisław Surma, Zeljko Reiner, Niki Katsiki, Peter E. Penson, Zlatko Fras, Amirhossein Sahebkar, Francesco Paneni, Manfredi Rizzo, John Kastelein
Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e693607bd1c9fad2a5af1ff6597ddf1
Autor:
Jorge Brantes Ferreira, João Morais, Elisabete Rodrigues, Francisco Araújo, Cristina Gavina, Ricardo Fontes-Carvalho, Pedro Marques da Silva
Publikováno v:
Revista Portuguesa de Cardiologia (English Edition), Vol 38, Iss 6, Pp 391-405 (2019)
Reducing low-density lipoprotein cholesterol (LDL-C) levels is one of the most important strategies for reducing the risk of cardiovascular events. However, in clinical practice, a high proportion of patients do not achieve recommended LDL-C levels t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73819ed09d39e2acadcfbc718a76b2a3
https://pubmed.ncbi.nlm.nih.gov/31324407
https://pubmed.ncbi.nlm.nih.gov/31324407
Autor:
Fruchart, J.C., Santos, R.D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P.J., Ceska, R., Corsini, A., Després, J.P., Duriez, P., Eckel, R.H., Ezhov, M.V., Farnier, M., Ginsberg, H.N., Hermans, M.P., Ishibashi, S., Karpe, F., Kodama, T., Koenig, W., Krempf, M., Lim, S., Lorenzatti, A.J., McPherson, R., Nuñez-Cortes, J.M., Nordestgaard, B.G., Ogawa, H., Packard, C.J., Plutzky, J., Ponte-Negretti, C.I., Pradhan, A., Ray, K.K., Reiner, Ž., Ridker, P.M., Ruscica, M., Sadikot, S., Shimano, H., Sritara, P., Stock, J.K., Su, T.C., Susekov, A.V., Tartar, A., Taskinen, M.R., Tenenbaum, A., Tokgözoğlu, L.S., Tomlinson, B., Tybjærg-Hansen, A., Valensi, P., Vrablík, M., Wahli, W., Watts, G.F., Yamashita, S., Yokote, K., Zambon, A., Libby, P.
Publikováno v:
Cardiovascular diabetology, vol. 18, no. 1, pp. 71
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::1e42e4b07a96300e14b1450540aec81b
https://serval.unil.ch/resource/serval:BIB_A62033B5071E.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_A62033B5071E.P001/REF.pdf
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Introduction: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in Portugal. Hypercholesterolemia has a causal role in atherosclerotic CVD. Guidelines recommend that cardiovascular (CV) risk reduction should be individualiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::42590429b62ef47e1fe2c88368341841
https://hdl.handle.net/10400.17/3857
https://hdl.handle.net/10400.17/3857
Autor:
John Costella, Benjamin Davidson, Gustavo Saposnik, Manav V. Vyas, Jorge G. Burneo, Leonardo Escalaya
Publikováno v:
Epilepsy Research. 113:44-67
Summary Objective To characterize the association between commonly used anti-epileptic drugs (AEDs) and plasma lipid levels in patients with epilepsy. Methods We sought observational studies that reported association between commonly used AEDs and pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1339062e1941f1517549d48317d487c6
https://doi.org/10.1016/j.eplepsyres.2015.03.002
https://doi.org/10.1016/j.eplepsyres.2015.03.002
Publikováno v:
European journal of clinical pharmacology, vol. 73, no. 9, pp. 1187-1194
This study aimed to assess the prevalence, the change, and the determinants of change in polypharmacy in a population-based sample. Baseline (2003–2006) and follow-up (2009–2012) data are from 4679 participants aged between 35 and 75 years (53.5%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eecc7e13cecf62ce6616f4e0f157cb7
https://pubmed.ncbi.nlm.nih.gov/28634642
https://pubmed.ncbi.nlm.nih.gov/28634642
The aim of the study was to compare the efficacy of high-dose rosuvastatin, low-dose rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega-3 fatty acids with regard to the lipid profile in patients with mixed hyperlipidemia. The primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::5d77aa7004eedd1481c1d16467684eb8
http://olympias.lib.uoi.gr/jspui/handle/123456789/21232
http://olympias.lib.uoi.gr/jspui/handle/123456789/21232
Cardiovascular disease (CVD) represents the leading cause of mortality worldwide. Lifestyle modifications, along with low-density lipoprotein cholesterol (LDL-C) reduction, remain the highest priorities in CVD risk management. Among lipid-lowering ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::85d7ed8d6222801a58f44d216669f2e8
http://olympias.lib.uoi.gr/jspui/handle/123456789/20211
http://olympias.lib.uoi.gr/jspui/handle/123456789/20211
The effect of statin treatment on glucose metabolism and the risk of diabetes remains an issue of controversy. Since statins are drugs commonly prescribed for the prevention of cardiovascular disease even in patients with prediabetes or diabetes, it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::02614b4be0c1dda4caf78263a294b7f0
http://olympias.lib.uoi.gr/jspui/handle/123456789/22394
http://olympias.lib.uoi.gr/jspui/handle/123456789/22394